Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: November 15, 2019

DrugPatentWatch Database Preview

HUMULIN 70/30 PEN Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Humulin 70/30 Pen, and when can generic versions of Humulin 70/30 Pen launch?

Humulin 70/30 Pen is a drug marketed by Lilly and is included in one NDA. There is one patent protecting this drug.

This drug has sixteen patent family members in twelve countries.

The generic ingredient in HUMULIN 70/30 PEN is insulin recombinant human; insulin susp isophane recombinant human. There are forty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the insulin recombinant human; insulin susp isophane recombinant human profile page.

Summary for HUMULIN 70/30 PEN
International Patents:16
US Patents:1
Suppliers / Packagers:2
Clinical Trials:24
Formulation / Manufacturing:see details
DailyMed Link:HUMULIN 70/30 PEN at DailyMed
Drug patent expirations by year for HUMULIN 70/30 PEN
Recent Clinical Trials for HUMULIN 70/30 PEN

Identify potential brand extensions & 505(b)(2) entrants

HealthPartners InstitutePhase 2
International Diabetes Center at Park NicolletPhase 2
Juvenile Diabetes Research FoundationPhase 2

See all HUMULIN 70/30 PEN clinical trials

US Patents and Regulatory Information for HUMULIN 70/30 PEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly HUMULIN 70/30 PEN insulin recombinant human; insulin susp isophane recombinant human INJECTABLE;INJECTION 019717-002 Aug 6, 1998 OTC Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for HUMULIN 70/30 PEN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2107069 C02107069/01 Switzerland   Start Trial PRODUCT NAME: INSULIN DEGLUDEC; REGISTRATION NO/DATE: SWISSMEDIC 62563 12.03.2013
2107069 C300597 Netherlands   Start Trial PRODUCT NAME: INSULINE DEGLUDEC EN INSULINE ASPART; REGISTRATION NO/DATE: EU/1/12/806/001EU/1/12/806/004EU/1/12/806/005EU/1/12/806/007EU/1/12/806/008 2013210121
0214826 C990042 Netherlands   Start Trial PRODUCT NAME: INSULIN ASPART; REGISTRATION NO/DATE: EU/1/99/119/001 - EU/1/99/119/005 19990907
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.